drugset / Trial / NCT06295549
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1
Terminated
11 enrolled
The First Affiliated Hospital with Nanjing Medical University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39P, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Timeline
- Start
- 2024-04-11
- Primary completion
- 2025-06-11
- Completion
- 2025-08-22
Outcome
Outcome not reported
Stopped: “Achieve the proof of concept.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUCAR-G39P | Cell therapy | — | — |